Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
暂无分享,去创建一个
L. Ashman | T. Hughes | Timothy P Hughes | Leonie K Ashman | P. Ferrao | Michelle J Frost | Petranel T Ferrao | T. Hughes
[1] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[2] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[3] R. Y. Chow,et al. A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. , 1999, The Biochemical journal.
[4] J. Melo,et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.
[5] S. Honsawek,et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] R. Cairoli,et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. , 1998, Blood cells, molecules & diseases.
[7] A. Bernstein,et al. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. , 1996, Blood.
[8] Y. Ma,et al. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.
[9] T. Hongyo,et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. , 2000, Cancer research.
[10] H. Kitayama,et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. , 1991, Blood.
[11] R. Arceci,et al. STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity , 2001, Oncogene.
[12] T. Nishida,et al. Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.
[13] Alastair,et al. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. , 1991, The EMBO journal.
[14] N. Sepp,et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. , 1998, The Journal of investigative dermatology.
[15] Y. Matsuzawa,et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation , 1994 .
[16] T. Hunter,et al. The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136 , 1998, Current Biology.
[17] L. Scott,et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. , 2000, Experimental Hematology.
[18] H. Kitayama,et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.
[19] R. Arceci,et al. Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells , 2001, Leukemia & lymphoma.
[20] F. Ruddle,et al. Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.
[21] L. To,et al. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. , 1994, Experimental hematology.
[22] G. Krystal,et al. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.
[23] Philip,et al. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. , 1993, Blood.
[24] W. Vainchenker,et al. A new c‐kit mutation in a case of aggressive mast cell disease , 1997, British journal of haematology.
[25] T. Kaisho,et al. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. , 1999, Blood.
[26] L. Ashman,et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.
[27] M. Carroll,et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.
[28] T Pawson,et al. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[29] L. Ashman,et al. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. , 1991, Blood.
[30] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[31] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[32] C. Moskaluk,et al. Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.
[33] Y. Matsuzawa,et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. , 1996, Blood.
[34] G. Basso,et al. Stem cell factor suppresses apoptosis in neuroblastoma cell lines. , 1997, Experimental hematology.
[35] Y. Suzuki,et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. DiPaola,et al. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. , 1997, Cancer gene therapy.
[37] Duc Hung Le,et al. SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain , 1998, Molecular and Cellular Biology.
[38] A. Chott,et al. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. , 2001, Leukemia research.
[39] T. Pawson,et al. The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor , 1991, Molecular and cellular biology.
[40] K.,et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c‐kit mutation Asp‐816 to Val , 1998, British journal of haematology.
[41] L. Ashman,et al. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. , 1997, Blood.
[42] K. Zsebo,et al. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. , 1992, Blood.
[43] L. Regan,et al. Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.
[44] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[45] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.
[46] Y. Satow,et al. c‐kit point mutation of extracellular domain in patients with myeloproliferative disorders , 1995, British journal of haematology.
[47] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[48] P. Valent,et al. Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis , 2001, British journal of haematology.
[49] Y. Matsuzawa,et al. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. , 1996, Blood.
[50] A. Bernstein,et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. , 1989, Genes & development.
[51] E Leonard,et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. , 2001, Blood.
[52] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[53] R. Salgia,et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.
[54] L. Ashman,et al. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia. , 1996, Leukemia.
[55] E. Scolnick,et al. Growth of factor-dependent hemopoietic precursor cell lines , 1980, The Journal of experimental medicine.
[56] L. Ashman,et al. Effects of mutant c-Kit in early myeloid cells. , 1999, Leukemia & lymphoma.
[57] H. Kitayama,et al. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. , 1996, The American journal of pathology.
[58] H. Griesser,et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia , 2000, Molecular pathology : MP.
[59] Y. Kitamura,et al. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase. , 1997, Leukemia.
[60] A. Kuraishi,et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. , 2001, Gastroenterology.
[61] S. Lev,et al. Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. , 1992, The Journal of biological chemistry.
[62] G. Dewald,et al. Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.
[63] Shan Zeng,et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. , 2002, Blood.
[64] C. Capella,et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa , 2001, Cancer.
[65] D. Metcalfe,et al. Clinical correlates of the presence of the asp816Val c‐kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis , 1998, Cancer.
[66] A. Ullrich,et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.
[67] J. Lasota,et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.
[68] T. Tsujimura. Role of c‐kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells , 1996, Pathology international.
[69] Laura H. Tang,et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.
[70] L. Kindblom,et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.
[71] C. Decastro,et al. Cloning and structural analysis of the human c-kit gene. , 1992, Oncogene.
[72] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[73] R. Arceci,et al. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. , 2001, Blood.
[74] Y. Matsuzawa,et al. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. , 1995, International archives of allergy and immunology.
[75] J. Litz,et al. Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors , 1999, Breast Cancer Research and Treatment.
[76] A. Kovatich,et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[77] D. Heitjan,et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[78] L. Ashman,et al. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts , 1999, Oncogene.
[79] N. Lydon,et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. , 1997, Blood cells, molecules & diseases.
[80] S. Hirota,et al. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats , 1997, Cell and Tissue Research.
[81] S. Hirota,et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.
[82] T Takahashi,et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.